Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
The product has been in-licensed from Strides and will be commercialized by Amneal
The company has received Form 483 with three observations
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
The product is expected to be launched in FY25
The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Subscribe To Our Newsletter & Stay Updated
